Effects of trimetazidine combined with levocarnitine on ischemic cardiomyopathy and serum levels of cardiac troponin I and homocysteine

We aim to evaluate the effects of trimetazidine combined with levocarnitine on ischemic cardiomyopathy and serum levels of cardiac troponin I (cTnI) and homocysteine (Hcy). A total of 208 elderly patients diagnosed with ischemic cardiomyopathy from June 2016 to June 2019 were randomly divided into two groups (n=104). The control group underwent conventional therapy for ischemic cardiomyopathy after admission, while the observation group were treated with levocarnitine injection combined with trimetazidine dihydrochloride tablets. The overall response rates of the observation and control groups were 83.65% and 68.27% respectively (P=0.009). Following treatment, the left-ventricular-end systolic diameter, the left-ventricular-end diastolic diameter and serum cTnI and Hcy levels declined significantly in both groups, and the decreases were more significant in the observation group at 2, 3 and 4 weeks after treatment (P<0.05). The incidence rates of adverse reactions in the observation and control groups were 10.58% and 7.69% respectively, without a significant difference (P=0.470). During follow-up, the risk of major adverse cardiovascular events in the control group was 2.08 times that of the observation group (P=0.008). Trimetazidine combined with levocarnitine can effectively improve the cardiac function and cTnI and Hcy levels in patients with ischemic cardiomyopathy. This combination helps improve the prognosis and does not significantly increase the incidence rate of adverse reactions.